URGENT: The COVID-19 epidemic is severely impacting the progress of ALS research at the ALS Therapy Development Institute. If you are able to give, will you please provide an immediate gift to fund our lab?

 

Neurimmune NI-204 / TDI 200

The misfolding of the antioxidant enzyme superoxide dismutase1 (SOD1) in motor neurons may contribute to ALS. A human-derived monoclonal antibody directed to misfolded SOD1, Neurimmune’s NI-204 aims to reduce the accumulation of misfolded SOD1 within motor neurons in people with ALS and thereby slow the progression of the disease.

Status

Type: Protein Biologic
Stage: Active
Status: Active
Sponsor: ALS Therapy Development Institute & Neurimmune

TDI Says:

Targeting misfolded SOD1, according to a growing number of studies, could be important in both the treatment of sporadic and familial forms of ALS. We look forward to further evaluating these antibodies as a potential treatment for the disease.

Learn More

  • SOD1 Off ALS

    Emerging strategies targeting misfolded SOD1 aim to slow or stop the spread of ALS - even in sporadic disease.

  • Charting the course of ALS

    A new map may help scientists design potential medicines that stop ALS in its tracks.

  • Antibodies for sALS?

    PALS that produce antibodies targeting misfolded SOD1 appear to live significantly longer according to a small study.

Published Results

Comment on this Topic

(All comments are moderated before they appear here.)